164 related articles for article (PubMed ID: 38587388)
41. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
42. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
[TBL] [Abstract][Full Text] [Related]
43. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
[TBL] [Abstract][Full Text] [Related]
44. Investigation of patient factors associated with the number of transfusions required during chemotherapy for high-risk neuroblastoma.
Konno S; Yanagisawa R; Kubota N; Ogiso Y; Nishimura N; Sakashita K; Tozuka M
Vox Sang; 2022 Jan; 117(1):71-79. PubMed ID: 34197634
[TBL] [Abstract][Full Text] [Related]
45. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
[TBL] [Abstract][Full Text] [Related]
46. Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance.
Bodensteiner DC; Doolittle GC
Drug Saf; 1993 Mar; 8(3):213-24. PubMed ID: 8452662
[TBL] [Abstract][Full Text] [Related]
47. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
48. Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.
Symann M
Curr Opin Oncol; 1991 Aug; 3(4):648-55. PubMed ID: 1932223
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction.
Estcourt LJ; Stanworth SJ; Hopewell S; Doree C; Trivella M; Massey E
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005339. PubMed ID: 27128488
[TBL] [Abstract][Full Text] [Related]
50. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
51. Myelopreservation with Trilaciclib in recurrent advanced ovarian cancer: a case report.
Tan H; Han X; Li C; Liu W; Li K; Sheng X; Qi S
Front Oncol; 2024; 14():1343239. PubMed ID: 38764584
[TBL] [Abstract][Full Text] [Related]
52. Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor.
Bartucci M; Dattilo R; Martinetti D; Todaro M; Zapparelli G; Di Virgilio A; Biffoni M; De Maria R; Zeuner A
Clin Cancer Res; 2011 Oct; 17(19):6185-91. PubMed ID: 21868766
[TBL] [Abstract][Full Text] [Related]
53. Role of supportive care in the treatment of NSCLC: supportive care for myelotoxicity.
Beinert T
Lung Cancer; 2002 Dec; 38 Suppl 3():S79-80. PubMed ID: 12468153
[TBL] [Abstract][Full Text] [Related]
54. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
55. Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor.
MacVittie TJ; Farese AM; Herodin F; Grab LB; Baum CM; McKearn JP
Blood; 1996 May; 87(10):4129-35. PubMed ID: 8639770
[TBL] [Abstract][Full Text] [Related]
56. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
[TBL] [Abstract][Full Text] [Related]
57. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer.
Paquette RL; Dergham ST; Karpf E; Wang HJ; Slamon DJ; Souza L; Glaspy JA
Blood; 2000 Oct; 96(7):2385-90. PubMed ID: 11001888
[TBL] [Abstract][Full Text] [Related]
58. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B
Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364
[TBL] [Abstract][Full Text] [Related]
59. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
